Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4257496 · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| LY4257496 Phase 1a Dose Escalation (Cohort A1) | EXPERIMENTAL | LY4257496 administered intravenously (IV) |
| LY4257496 Phase 1a Dose Optimization (Cohort A2) | EXPERIMENTAL | LY4257496 administered IV |
| LY4257496 + Standard of Care Phase 1b Cohort B | EXPERIMENTAL | Tumor specific cohort will receive LY4257496 alone or with standard of care anticancer therapy(ies) |
| LY4257496 Phase 1b Cohort C | EXPERIMENTAL | Tumor specific cohort will receive LY4257496 |
| LY4257496 Phase 1b Cohort D | EXPERIMENTAL | Tumor specific cohort will receive LY4257496 |
| Name | Type | Description |
|---|---|---|
| LY4257496 | DRUG | Administered IV |
| Standard of Care Anticancer Therapies | DRUG | Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib |
| LY4257529 | DIAGNOSTIC_TEST | Administered IV at select sites |
Inclusion Criteria: * Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer. * Must be assessed by computed tomography (CT)/magnetic resonance imaging (MRI) to confirm at least 1 of the following: * At least 1 measurable target lesion ...
LY4257496 is an investigational small molecule being studied for the treatment of breast neoplasms, as well as other cancers including colorectal, prostate, endometrial, stomach, and esophageal neoplasms, and neoplasm metastasis. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
LY4257496 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being investigated in oncology for its potential anti-cancer activity across multiple tumor types, including breast, colorectal, prostate, and endometrial cancers.
LY4257496 is being developed by Eli Lilly and Company, a pharmaceutical company publicly traded under the ticker symbol LLY on the New York Stock Exchange. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in cancer patients.
LY4257496 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is actively recruiting participants to study the drug in patients with various types of cancer.
LY4257496 is being studied in a Phase 1 clinical trial with the identifier NCT07114601, titled "A Study of LY4257496 in Participants With Cancer (OMNIRAY)." This recruiting trial has an estimated enrollment of 421 participants and is being conducted in the United States, Canada, China, France, Germany, Japan, and Spain.
LY4257496 is the drug being studied in the clinical trial referred to as OMNIRAY. The trial title is "A Study of LY4257496 in Participants With Cancer (OMNIRAY)," indicating that OMNIRAY is the study name or program name for this investigational drug, not a separate drug entity.